On May 14, 2014, Daqo New Energy Corp (NYSE:DQ) announced that the previously announced registered follow-on public offering of American depositary shares (“ADSs”) by the Company was priced at US$29.00 per ADS on May 14, 2014. The Company will issue and sell 2,000,000 ADSs. Each ADS represents 25 ordinary shares of the Company. In connection with this offering, the Company has granted the underwriter a 30-day option to purchase up to 300,000 additional ADSs. Daqo New Energy Corp (NYSE:DQ) n weekly performance is -29.91%. On last trading day company shares ended up $25.10. Daqo New Energy Corp (NYSE:DQ) distance from 50-day simple moving average (SMA50) is -40.78%.
On may 6, Rubicon Technology, Inc. (NASDAQ:RBCN) announced that the company will showcase its line of high quality optical products for use in defense and aerospace, instrumentation and analytical processing, sensors and detectors, semiconductor process equipment, and medical and laser applications at the SPIE Defense, Security and Sensing 2014 exhibition from May 6 to 9 at the Baltimore Convention Center in booth #1032. Rubicon Technology, Inc. (NASDAQ:RBCN) shares fell -5.76% in last trading session and ended the day on $7.20. RBCN Gross Margin is -54.70% and its return on assets is -17.30%. Rubicon Technology, Inc. (NASDAQ:RBCN) quarterly performance is -34.07%.
Cree (NASDAQ:CREE) was the target of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 13,154,114 shares, an increase of 13.6% from the April 15th total of 11,577,511 shares, Stock Ratings News reports. Based on an average daily volume of 4,643,643 shares, the days-to-cover ratio is presently 2.8 days. Currently, 11.0% of the company’s shares are sold short. Cree, Inc. (NASDAQ:CREE) ended the last trading day at $45.41. Company weekly volatility is calculated as 1.97% and price to cash ratio as 4.53. Cree, Inc. (NASDAQ:CREE) showed a positive weekly performance of 0.02%.
On May 6, 2014, Intermolecular Inc (NASDAQ:IMI) announced results for its first quarter ended March 31, 2014. Revenue for the first quarter of 2014 was $15.9 million, a decline of 9% on a year-over-year basis from $17.4 million in the year-ago period, but up slightly from the prior quarter’s revenue of $15.6 million. Collaborative development program (CDP) revenue was $8.9 million for the quarter, compared to $10.9 million in the prior year period. Licensing and royalty revenue was $7.0 million, compared to $3.4 million for the same period a year ago, which included an accelerated payment from GLOBALFOUNDRIES in connection with the suspension of the collaborative development program and activities with them. There was no reported revenue from product sales, compared to product revenue of $3.1 million in the year-ago period.Intermolecular Inc (NASDAQ:IMI) shares moved up 0.93% in last trading session and was closed at $2.17, while trading in range of $2.10 – $2.19. Intermolecular Inc (NASDAQ:IMI)year to date (YTD) performance is -55.89%.
Leave a Reply